Co-Diagnostics Inc (CODX)

[Opti Mist]

Tuberculosis kills 1,000 people a day roughly in India and has done for many, many years, does the same in China. We are now going to be entering into a world where our proprietary CoPrimer technology is going to be applied against a whole bunch of other infections. There are roughly 1 million STI infections a day in the world. And these are the kinds of things that we're going to be interrogating as we go into the future. We're also working closely with certain NGOs around the world who are participating and trying to provide solutions to things like tuberculosis, which frankly have been rather ignored during the COVID pandemic, which is ongoing.

And we are anticipating some material ramifications of those NGOs in dealing with our new platform, which enables them to put a very inexpensive solution in the hands of laboratories and governments and other end users around the world with the device that costs in the neighborhood of $300 at retail and tests that are very inexpensive compared to what's offered by the competition. You also asked about our competition. We really believe that our device stands by itself and speaks for itself in terms of how it competes with what else is out there. This is not an antigen test. It's not an isothermal or LAMP technology test.